公开(公告)号：US20220331309A1

公开(公告)日：2022-10-20

申请号：US17636133

申请日：2020-08-19

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Ishani Savant Landry ,  Kenya Nakai ,  Yukiko Miyajima ,  Yosuke Nakatani ,  Takashi Ueno ,  Edgar Schuck

IPC: A61K31/496 ,  A61K31/4709 ,  A61K31/70 ,  A61P43/00 ,  A61K31/135 ,  A61K38/00

Abstract: The present invention provides an oral pharmaceutical composition for treating insomnia, comprising lemborexant or a pharmaceutically acceptable salt thereof, wherein a normal dose of the lemborexant or pharmaceutically acceptable salt thereof is 5 to 10 mg per day, provided that a dose of the lemborexant or pharmaceutically acceptable salt thereof is 2.5 mg per day when the pharmaceutical composition is administered to a patient together with the agent capable of moderately or strongly inhibiting CYP3A, and/or a dose of the lemborexant or pharmaceutically acceptable salt thereof is 5 mg per day when the pharmaceutical composition is administered to the patient together with the agent capable of weakly inhibiting CYP3A.

公开(公告)号：US20220378706A1

公开(公告)日：2022-12-01

申请号：US17831863

申请日：2022-06-03

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Edgar Schuck ,  Robert Lai ,  Ishani Savant Landry ,  Bhaskar Rege ,  Mai Miyamoto ,  Sadaharu Kotani ,  Kanta Horie

IPC: A61K9/20 ,  A61P25/28 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437

Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.

公开(公告)号：US11484502B2

公开(公告)日：2022-11-01

申请号：US16609514

申请日：2018-05-30

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Edgar Schuck ,  Robert Lai ,  Ishani Savant Landry ,  Bhaskar Rege ,  Mai Miyamoto ,  Sadaharu Kotani ,  Kanta Horie

IPC: A61K9/20 ,  A61P25/28 ,  A61K9/16 ,  A61K9/48 ,  A61K31/437

Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.

公开(公告)号：US20200078306A1

公开(公告)日：2020-03-12

申请号：US16609514

申请日：2018-05-30

Applicant: Eisai R&D Management Co., Ltd.

Inventor： Edgar Schuck ,  Robert Lai ,  Ishani Savant Landry ,  Bhaskar Rege ,  Mai Miyamoto ,  Sadaharu Kotani ,  Kanta Horie

IPC: A61K9/20 ,  A61K31/437 ,  A61P25/28 ,  A61K9/48 ,  A61K9/16

Abstract: The present invention provides a pharmaceutical composition comprising a PDE9 inhibitor. Specifically, the PDE9 inhibitor is (S)-7-(2-methoxy-3,5-dimethylpyridin-4-yl)-1-(tetrahydrofuran-3-yl)-1H-pyrazolo[4,3-c]quin olin-4(5H)-one or pharmaceutically acceptable salts thereof.